Shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) have received an average recommendation of “Buy” from the six brokerages that are covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have covered the stock in the last year is $5.50.
Several equities research analysts have issued reports on AVEO shares. BidaskClub raised shares of AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, September 11th. HC Wainwright started coverage on shares of AVEO Pharmaceuticals in a research report on Thursday, August 16th. They issued a “buy” rating and a $6.50 price objective for the company.
In related news, major shareholder Equity Opportunities Iv Growth acquired 663,716 shares of the stock in a transaction on Tuesday, August 21st. The stock was bought at an average cost of $2.26 per share, with a total value of $1,499,998.16. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.40% of the stock is owned by insiders.
AVEO Pharmaceuticals stock opened at $2.53 on Tuesday. The stock has a market capitalization of $317.81 million, a price-to-earnings ratio of -15.81 and a beta of 1.67. The company has a debt-to-equity ratio of -0.36, a current ratio of 1.16 and a quick ratio of 1.16. AVEO Pharmaceuticals has a 1 year low of $1.86 and a 1 year high of $3.59.
AVEO Pharmaceuticals (NASDAQ:AVEO) last released its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.09). The business had revenue of $0.43 million for the quarter, compared to the consensus estimate of $1.35 million. As a group, research analysts expect that AVEO Pharmaceuticals will post -0.25 earnings per share for the current fiscal year.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Featured Story: What is a Call Option?
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.